Topic desk · 6 reviewed briefs
Metabolic peptide medicines
Compare approved products, investigational agonists, and wellness-market fragments without treating them as one category.
Evidence boundary
A large weight or glucose result belongs to the studied molecule, product, population, endpoint, and duration. It does not validate every version sold under an ingredient name.
- Reviewed briefs
- 6
- Established contexts
- 4
- Reviewed claims
- 18
Before accepting a claim
Ask the question the promotion leaves out.
- 01
Is there an approved product, an investigational program, or neither?
- 02
Was the endpoint weight, glucose, cardiovascular events, or only a biomarker?
- 03
Does the claim preserve the studied population and product?
Connected briefs
Compare evidence without flattening it.
Semaglutide
A prescription peptide medicine with established uses, product-specific labels, and an important divide between approved and unapproved versions.
3 reviewed claims · Open brief ↗Insulin
A natural peptide hormone and foundational family of diabetes medicines whose effects, risks, and use depend on the exact product and care plan.
3 reviewed claims · Open brief ↗Tirzepatide
A dual GIP and GLP-1 receptor agonist with approved products and large human trials, bounded by product-specific indications, labels, and safety information.
3 reviewed claims · Open brief ↗Liraglutide
An established GLP-1 medicine whose evidence belongs to specific products, indications, populations, and current labels.
3 reviewed claims · Open brief ↗Retatrutide
A triple-receptor investigational peptide with meaningful late-stage human results but no approved product or completed regulatory review.
3 reviewed claims · Open brief ↗AOD-9604
A modified growth-hormone fragment studied in obesity programs without an approved use and with unresolved route, product, and safety questions.
3 reviewed claims · Open brief ↗